An interventional study of IV vancomycin in Infection, Sepsis and Obesity, sponsored by CAMC Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by CAMC Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.
Among the 517 studies in Sepsis with a site in United States, this one is the 162nd largest by enrollment of the 310 interventional ones that give a count, is one of 23 that started in 2016, is one of 140 with no phase, and was the 248th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:
Deepull Diagnostics S.L. · Sites in United States, France, Germany and 2 more countries
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 0 days–7 days
Vanderbilt University Medical Center · Sites in United States
Ages 1 days–12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 80 · Phase 3 47 · Phase 4 25
First in 1988; this study’s year is marked. 23 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 84 across the 310 interventional studies, 183 across the 204 observational. Of the 361 that completed or were terminated, 117 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 517 have an industry lead sponsor. The 10 most frequent:
CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
CAMC Health System has 2 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
37 of the studies in Sepsis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT03133208University of FloridaSepsis Associated Encephalopathy (SAE) Biomarkers | 2026-12-15 |
Add all 37 to your calendar (.ics) → With an account.
Among the 517 studies in Sepsis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity alters the movement through the body of several antibiotics, including vancomycin. Based on literature to date, total body weight should be used to determine dosages and shorter dosing intervals may be needed. However, hospitals have different approaches to managing vancomycin in this patient population. The most common example is not exceeding a dose of 2,000mg of vancomycin at one time in these patients. However, some institutions including the Charleston Area Medical Center do not have a set maximum one time dose. To date, a study has not been done comparing two different dosing regimens in obese patients to determine if having a maximum dose cap is beneficial.
This research study is attempting to add to the limited existing body of literature regarding vancomycin dosing in obese patients. The investigators hypothesize that optimizing the initial or loading vancomycin dose that obese patients receive will decrease the time to target concentrations. For this study, obese adult patients will be randomized to receive either 1) a loading dose of 20 mg/kg with a maximum dose up to 2,000mg OR 2) a loading dose of 20 mg/kg with a maximum dose of up to 4,000mg. The study's primary aim is to determine differences in the time needed to achieve target vancomycin concentrations and the occurrence of adverse events.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's enrollment of 76 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Browse Sepsis studies →CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
Drug: IV vancomycin
IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
Drug: IV vancomycin
IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
Time to Attain Therapeutic Vancomycin Concentrations.
Time to attain therapeutic vancomycin concentrations was measured in hours. Therapeutic vancomycin concentrations were set as 15-20 mg/L in patients with serious, documented Gram-positive infections (e.g., endocarditis, meningitis, pneumonia, osteomyelitis), while in patients with a lower risk of Gram-positive infections (e.g., pyelonephritis, skin/tissue structured infections), therapeutic vancomycin concentrations were defined as 10-15 mg/L.
Time frame: Time Frame: 20 days
Number of Participants With Reported Adverse Events (AE)
Red Man's syndrome: pruritus and erythematous rash involving the face, neck, and upper torso. Red Man's syndrome is an older term for vancomycin flushing syndrome (VFS). Nephrotoxicity: increase in serum creatinine (SCr) by 0.5 mg/dL or 50% from baseline on two consecutive measurements.
Time frame: 48 hours post initial vancomycin dose
Examine the Pharmacokinetic Parameter of Elimination Rate Constant (ke) Following the Loading Vancomycin Dose
These measurements assessed the elimination rate constant of vancomycin between the two treatment regimens. Two elimination rate constants were assessed: Elimination constant at 7.5-hour trough level and Elimination constant at initial trough level.
Time frame: 12 hours
Intensive Care Unit Length of Stay
The duration of time participants spent in the intensive care unit (ICU) during their hospitalization. This outcome measures the total number of days spent in the ICU, from ICU admission to discharge from ICU.
Time frame: 30 days
Hospital Length of Stay
The total duration of hospitalization, measured from the time of hospital admission to discharge.
Time frame: 60 days
In-hospital Mortality
The percentage of participants that died during their hospital stay. This measure assesses the mortality rate from the time of hospital admission until discharge or death.
Time frame: 60 days
| Milestone | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Started | 37 | 39 |
| Completed | 34 | 33 |
| Not completed | 3 | 6 |
| Withdrew: Length of stay less than 24 hours | 1 | 2 |
| Withdrew: Elevated serum creatinine post-consent | 1 | 0 |
| Withdrew: Non-randomized dose | 0 | 1 |
| Withdrew: Incomplete consent documentation | 1 | 3 |
Time to attain therapeutic vancomycin concentrations was measured in hours. Therapeutic vancomycin concentrations were set as 15-20 mg/L in patients with serious, documented Gram-positive infections (e.g., endocarditis, meningitis, pneumonia, osteomyelitis), while in patients with a lower risk of Gram-positive infections (e.g., pyelonephritis, skin/tissue structured infections), therapeutic vancomycin concentrations were defined as 10-15 mg/L.
| hours | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Time to Attain Therapeutic Vancomycin Concentrations. | 26.2 (7.8 to 180.8) | 16.6 (4.6 to 457.6) |
Red Man's syndrome: pruritus and erythematous rash involving the face, neck, and upper torso. Red Man's syndrome is an older term for vancomycin flushing syndrome (VFS). Nephrotoxicity: increase in serum creatinine (SCr) by 0.5 mg/dL or 50% from baseline on two consecutive measurements.
| Number of Participants with AE | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Red man syndrome/ vancomycin flushing syndrome | 1 | 0 |
| Nephrotoxicity | 4 | 0 |
These measurements assessed the elimination rate constant of vancomycin between the two treatment regimens. Two elimination rate constants were assessed: Elimination constant at 7.5-hour trough level and Elimination constant at initial trough level.
| 1/hours | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Elimination constant at 7.5-hour trough level | 0.17 ± 0.09 | 0.26 ± 0.12 |
| Elimination constant at initial trough level | 0.39 ± 0.18 | 0.49 ± 0.21 |
The duration of time participants spent in the intensive care unit (ICU) during their hospitalization. This outcome measures the total number of days spent in the ICU, from ICU admission to discharge from ICU.
| days | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Intensive Care Unit Length of Stay | 0.0 (0.0 to 16.0) | 0.0 (0.0 to 22.0) |
The total duration of hospitalization, measured from the time of hospital admission to discharge.
| days | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| Hospital Length of Stay | 6.5 (2.0 to 24.0) | 6.0 (0.0 to 59.0) |
The percentage of participants that died during their hospital stay. This measure assesses the mortality rate from the time of hospital admission until discharge or death.
| Participants | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| In-hospital Mortality | 1 | 0 |
Collected over Adverse events were collected systematically through renal function monitoring at baseline, 24, and 48 hours post-vancomycin. Nephrotoxicity was defined as a 0.5 mg/dL or 50% rise in serum creatinine. Vancomycin Flushing Syndrome was tracked based on symptoms like rash and pruritus. All-cause mortality was recorded through the hospital stay, up to 60 days. Data were collected prospectively according to the protocol.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Vancomycin Loading Dose- Higher | 1/34 (2.9%) | 4/34 (11.8%) | 0/34 (0%) |
| IV Vancomycin Loading Dose- Lower | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) |
| Event | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower |
|---|---|---|
| NephrotoxicityRenal and urinary disorders | 4/34 | 0/33 |
| Red man's/Vancomycin flushing syndrome (VFS)Skin and subcutaneous tissue disorders | 1/34 | 0/33 |
The baseline analysis population includes all participants who completed the study in each arm. No deviations in the baseline population occurred, and the analysis was based solely on participants, with no additional unit-based contributions.
| Age, Categorical(Participants) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 22 | 48 |
| >=65 years | 8 | 11 | 19 |
| Age, Continuous(years) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| Mean | 53.5 ± 13.7 | 60.0 ± 12.0 | 56.7 ± 13.2 |
| Sex: Female, Male(Participants) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| Female | 19 | 23 | 42 |
| Male | 15 | 10 | 25 |
| Race (NIH/OMB)(Participants) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 32 | 32 | 64 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| United States | 34 | 33 | 67 |
| Body Mass Index (BMI)(kg/meters(squared)) | IV Vancomycin Loading Dose- Higher | IV Vancomycin Loading Dose- Lower | Total |
|---|---|---|---|
| Median | 41.5 (31.1 to 83.2) | 42.3 (30.6 to 97.9) | 42.0 (30.6 to 97.9) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Apr 2024, 92 months.
Results were first posted in Oct 2026, 2 years 6 months after primary completion.
Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 92 months is above that.
Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jan 2021 → Apr 2024 and completion Jan 2021 → Apr 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin
CAMC Health System